Fig. 2: RBM15 contributes to the growth and motility of TNBC cells.

a–g The indicated TNBC cells were stably transfected with shRBM15 or control shRNA (shGFP) and analyzed by western blotting (WB) analysis using the indicated antibodies (a) and by qRT‒PCR analysis (b). The infected cells were analyzed by a proliferation assay (CCK-8 assay) (c), a colony formation assay (d), and FACS analysis (e). The infected cells were subjected to cell migration assays using Boyden chambers (f). Boyden chamber Transwell assays were conducted without ECM for 36 h, and the migratory capacity of the cells was quantified by counting the number of stained cells. Cell invasion was analyzed using Boyden chambers, with Matrigel functioning as the ECM (g). The cells in the invasion assay were incubated for 36 h at 37 °C and stained with crystal violet. All the cells were quantified. h–k Xenograft experiments. MDA-MB-231 cells were infected with shRBM15 or control shRNA (shGFP) and selected with puromycin. After the infected MDA-MB-231 cells were injected into nude mice (h), the tumor volumes (i) and weights (j) were measured (n = 10). A representative IHC analysis of mouse samples was performed (k). All results are expressed as the means ± standard deviations (SDs) from three independent replicates (*p < 0.05, **p < 0.01, ***p < 0.005, and ****p < 0.001).